טיגציל ישראל - עברית - Ministry of Health

טיגציל

pfizer pharmaceuticals israel ltd - tigecycline - אבקה מיובשת בהקפאה לאינפוזיה - tigecycline 50 mg/dose - tigecycline - tigecycline - tygacil is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years of age and older:complicated skin and skin structure infections:complicated skin and skin structure infections caused by escherichia coli, enterococcus faecalis (vancomycin-susceptible isolates ), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus agalactiae, streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus), streptococcus pyogenes, enterobacter cloacae, klebsiella pneumoniae, and bacteroides fragilis .complicated intra-abdominal infections:complicated intra-abdominal infections caused by citrobacter freundii, enterobacter cloacae, escherichia coli, klebsiella oxytoca, klebsiella pneumoniae, enterococcus faecalis (vancomycin-susceptible isolates), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus anginosus grp. (includes s. anginosu

טיגציל ישראל - עברית - Ministry of Health

טיגציל

pfizer pfe pharmaceuticals israel ltd - tigecycline - אבקה להכנת תמיסה לאינפוזיה - tigecycline 50 mg/dose - tigecycline - tigecycline - tygacil is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years of age and older:complicated skin and skin structure infections:complicated skin and skin structure infections caused by escherichia coli, enterococcus faecalis (vancomycin-susceptible isolates ), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus agalactiae, streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus), streptococcus pyogenes, enterobacter cloacae, klebsiella pneumoniae, and bacteroides fragilis .complicated intra-abdominal infections:complicated intra-abdominal infections caused by citrobacter freundii, enterobacter cloacae, escherichia coli, klebsiella oxytoca, klebsiella pneumoniae, enterococcus faecalis (vancomycin-susceptible isolates), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus anginosus grp. (includes s. anginosu

לשקוטאן משחה ישראל - עברית - Ministry of Health

לשקוטאן משחה

teva israel ltd - methylbenzethonium chloride; paromomycin as sulfate - משחה - methylbenzethonium chloride 12 %w/w; paromomycin as sulfate 15 %w/w - paromomycin - paromomycin - topical treatment of cutaneous leishmaniasis.

קיוביצין 500 מ"ג ישראל - עברית - Ministry of Health

קיוביצין 500 מ"ג

medison pharma ltd - daptomycin 500 mg/vial - lyophilized powder for injection - daptomycin - cubicin (daptomycin for injection) is indicated for the treatment of complicated skin and skin structure infections caused by susceptible strains of the following gram-positive microorganisms: staphylococcus aureus (including methicillin-resistant strains) streptococcus pyogenes streptococcus agalactiae streptococcus dysgalactiae subsp. equisimilis and enterococcus faecalis (vancomycin-susceptible strains only). combination therapy may be clinically indicated if the documented or presumed pathogens include gram-negative or anaerobic organisms. daptomycin is not indicated for the treatment of pneumonia. appropriate specimens for microbiological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to daptomycin. empiric therapy may be initiated while awaiting test results. antimicrobial therapy should be adjusted as needed based upon test results. to reduce the development of drug-resistant bacteria and maintain the effectiveness of cubici

דיפיקליר ישראל - עברית - Ministry of Health

דיפיקליר

tradis gat ltd - fidaxomicin - טבליות מצופות פילם - fidaxomicin 200 mg - fidaxomicin

פריוריקס ישראל - עברית - Ministry of Health

פריוריקס

glaxo smith kline (israel) ltd - live attenuated measles virus; live attenuated mumps virus; live attenuated rubella virus - אבקה וממס להכנת תמיסה להזרקה - live attenuated mumps virus 10^3.7 ccid50; live attenuated rubella virus 10^3.0 ccid50; live attenuated measles virus 10^3.0 ccid50 - rubella, combinations with mumps, live attenuated - rubella, combinations with mumps, live attenuated - priorix is indicated for active immunisation of children from the age of 9 months or older, adolescents and adults against measles, mumps and rubella.

ורילריקס ישראל - עברית - Ministry of Health

ורילריקס

glaxo smith kline (israel) ltd - varicella virus, live attenuated - אבקה וממס להכנת תמיסה להזרקה - varicella virus, live attenuated nlt 10^3.3 pfu - varicella zoster vaccines - in the event of negative anamnesis, for the active immunisation against varicella in healthy subjects only from the age of 12 months.

טיקוואק 0.5 מל ישראל - עברית - Ministry of Health

טיקוואק 0.5 מל

pfizer pharmaceuticals israel ltd - encephalitis, tick borne, inactivated, whole virus - תרחיף להזרקה - encephalitis, tick borne, inactivated, whole virus 2.4 mcg / 0.5 ml - encephalitis, tick borne, inactivated, whole virus

טיקוואק ג'וניור 0.25 מל ישראל - עברית - Ministry of Health

טיקוואק ג'וניור 0.25 מל

pfizer pharmaceuticals israel ltd - encephalitis, tick borne, inactivated, whole virus - תרחיף להזרקה - encephalitis, tick borne, inactivated, whole virus 1.2 mcg / 0.25 ml - encephalitis, tick borne, inactivated, whole virus